Clinical trial • Phase IV • Neurology
Pregabalin for Peripheral neuropathic pain
Phase IV trial of Pregabalin for Peripheral neuropathic pain. 40 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Peripheral neuropathic pain
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 01-11-2024
- First CTIS Authorization Date
- 14-11-2024
Trial design
Phase IV trial across 2 sites in Finland.
- Target Sample Size
- 40
- Trial Duration For Participant
- 365
Eligibility
Recruits 40 No vulnerable population selected; participants are adults (age 18-75)..
- Vulnerable Population
- No vulnerable population selected; participants are adults (age 18-75).
Inclusion criteria
- {"criterion_text":"-Patients with peripheral painful neuropathy, age 18-75 years, pain is chronic (duration >3 months) and moderate to severe intensity (NRS ≥ 4/10) aiming to recruit 20 patients with at least a moderate sleep disturbance as assessed with ISI-questionnaire (>14) and 20 patients without sleep disturbance."}
Exclusion criteria
- {"criterion_text":"-Excessive alcohol consumption (>7 doses/week). If the patient uses gabapentinoids (gabapentin or pregabalin), they are discontinued 2 weeks before the study. Psychotic depression, clinically significant bipolar disorder. Contraindications to brain fMRI."}
Endpoints
Primary endpoints
- {"endpoint_text":"-Pregabalin response to pain. Pain intensity and interference assessed by numeric rating scale","definition_or_measurement_approach":"Pain intensity and interference assessed by numeric rating scale"}
Secondary endpoints
- {"endpoint_text":"-Pregabalin effect on sleep stages. 1-night Ambulatory Polysomnography (NREM stage III).","definition_or_measurement_approach":"1-night Ambulatory Polysomnography (NREM stage III)"}
- {"endpoint_text":"-Sleep disturbance associations to brain network connectivity. Brain fMRI for brain network connectivity","definition_or_measurement_approach":"Brain fMRI for brain network connectivity"}
- {"endpoint_text":"-Sleep disturbance associations to choroid plexus volume in brain fMRI. Brain fMRI for choroid plexus volume measures","definition_or_measurement_approach":"Brain fMRI for choroid plexus volume measures"}
- {"endpoint_text":"-Pregabalin effect on circadian rhythms. 1-week actigraphy and OURA-ring","definition_or_measurement_approach":"1-week actigraphy and OURA-ring to assess circadian rhythms"}
- {"endpoint_text":"-Pregabalin effect on body temperature during sleep. 1-night body temperature measurement by iButton","definition_or_measurement_approach":"1-night body temperature measurement by iButton"}
Recruitment
- Planned Sample Size
- 40
- Recruitment Window Months
- 37
- Consent Approach
- Informed consent obtained from adult participants; a Subject information and informed consent form is listed among study documents.
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 40
Finland
- Earliest CTIS Part Ii Submission Date
- 01-11-2024
- Latest Decision Or Authorization Date
- 14-11-2024
- Processing Time Days
- 13
- Number Of Sites
- 2
- Number Of Participants
- 40
Sites
- Site Name
- HUS-Yhtymae
- Department Name
- Neurology
- Contact Person Name
- Hanna Harno
- Contact Person Email
- hanna.harno@hus.fi
- Site Name
- HUS-Yhtymae
- Department Name
- Neurology
- Contact Person Name
- Hanna Harno
- Contact Person Email
- hanna.harno@hus.fi
Sponsor
Primary sponsor
- Full Name
- HUS-Yhtymae
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Finland
Investigational products
- Investigational Product Name
- Lyrica 25 mg hard capsules
- Active Substance
- Pregabalin
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Authorised
- Starting Dose
- 25 mg
- Dose Levels
- 25 mg
- Maximum Dose
- 600 mg/day
- Investigational Product Name
- Lyrica 75 mg hard capsules
- Active Substance
- Pregabalin
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Authorised
- Starting Dose
- 75 mg
- Dose Levels
- 75 mg
- Maximum Dose
- 600 mg/day
- Investigational Product Name
- Pregabalin Pfizer 150 mg hard capsules
- Active Substance
- Pregabalin
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Authorised
- Starting Dose
- 150 mg
- Dose Levels
- 150 mg
- Maximum Dose
- 600 mg/day
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke